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Medicinal Genome Editing in Germany – 
Tensions Between Safeguarding and 
Circumventing Ethical and Legal Standards  
BY TIMO FALTUS* 
Abstract: Recent breakthroughs in the research and application of 
genome editing techniques could provide new opportunities for the fur-
ther development of gene therapy. Irrespective of the achievements al-
ready observed and the opportunities that have been predicted so far, 
there are still questions remaining about the ethical, legal, and regulatory 
(ELSI) framework for both the research and application of this technol-
ogy in medicine. This article provides an overview of the legal framework 
for the medical research and application of genome editing techniques in 
Germany, considering the legal multi-level system of the European Un-
ion (EU) and Germany. This article explains the legal loopholes in current 
legislation that make the dubious use of genome editing techniques de 
facto possible, particularly in its medical applications in somatic gene 
therapy and germline gene therapy. The article also discusses proposals 
for the further development of the legal framework for using genome ed-
iting. 
I.  INTRODUCTION – WHAT IS SO SPECIAL ABOUT GENOME EDITING 
TECHNIQUES? 
Genome editing methods, unlike other genetic engineering methods 
such as virus-based transduction methods or chemical transfections, have 
managed to create interest outside of empirical sciences. In fact, these 
methods attracted the attention of ELSI researchers, as well as the 
 
* Research Fellow, Faculty of Law, Economics and Business, Martin-Luther-University Halle-Wit-
tenberg, Germany. The paper was written in the context of the project “Human Germline Genome 
Modification and the Right to Science” initiated by Andrea Boggio, Cesare P.R. Romano, and Jes-
sica Almqvist, and the contributing author is the sole author of this paper. The research presented 
here was made possible by funding from the German Federal Ministry of Education and Research 
(BMBF), Grant No. 01GP1614A within the research project “Genome Editing – Ethical, Legal, 
and Science Communication Aspects in Molecular Medicine and Crop Plant Engineering.” 
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attention of the public.1 Why is that? The methods in question, which 
mainly include CRISPR-Cas, zinc-finger nucleases (ZFNs), and tran-
scription activator-like effector nucleases (TALENs), have been explored 
for decades.2 Though they each have a naturally occurring origin, these 
methods have long stayed under the perceptual radar of ELSI research 
and the public. This perception started to shift about nine years ago, 
mainly due to the application-based breakthrough (i.e., the transfer of 
basic research into practical applications of daily life), especially in rela-
tion to the CRISPR-Cas method. The main catalyst for this seems to be 
that, with the now perfected editing methods, human DNA can be altered 
in a way that is faster, easier, cheaper, and more accurate than what was 
previously possible with past methods of genetic engineering. At first 
glance, these innovations highlight the use of genome editing in human 
medicine, and the potential they have to possibly improve gene therapy 
approaches. Therefore, it is not surprising that scientists are swiftly push-
ing genome editing forward to help further the development of somatic 
gene therapy.3 It is also not surprising that the age-old debate surrounding 
the moral status of targeted germline alterations has been rekindled due 
to these recent innovations in genome editing.4 Several parties have al-
ready demanded a moratorium, effectively asking that targeted germline 
alterations not be carried out for the time being.5 Generally speaking, as 
 
 1. Heidi C. Howard et al., One Small Edit for Humans, One Giant Edit for Humankind? 
Points and Questions to Consider for a Responsible Way Forward for Gene Editing in Humans, 26 
EUR. J. HUM. GENETICS 1, 1 (2018); Ana Nordberg et al., Cutting Edges and Weaving Threads in 
the Gene Editing (Я)evolution: Reconciling Scientific Progress with Legal, Ethical, and Social 
Concerns, 5 J. L. AND BIOSCIENCES 35, 36 (2018). 
 2. See Dana Carroll, Genome Editing: Past, Present, and Future, 90 YALE J. BIOLOGY AND 
MED. 653 (2017); Almudena Fernández et al., A History of Genome Editing in Mammals, 28 
MAMMALIAN GENOME 237 (2017); Puping Liang et al., Developmental History and Application of 
CRISPR in Human Disease, 19 J. GENE MED. 6 (2017). 
 3. See Daniel P. Dever & Matthew H. Porteus, The Changing Landscape of Gene Editing in 
Hematopoietic Stem Cells: A Step Towards Cas9 Clinical Translation, 24 CURRENT OP. 
HEMATOLOGY 481 (2017); Simone A. Haas, Viviane Dettmer, Toni Cathomen, Therapeutic Ge-
nome Editing with Engineered Nucleases, 37 HÄMOSTASEOLOGIE 45 (2017); Nataša Savić & Ger-
ald Schwank, Advances in Therapeutic CRISPR/Cas9 Genome Editing, 168 TRANSLATIONAL RES. 
15 (2016). 
 4. For a recent overview of the international debate on the interaction of germline gene mo-
dification and the right to science, see Andrea Boggio, Bartha M. Knoppers, Jessica Almqvist, & 
Cesare Romano, The Human Right to Science and the Regulation of Human Germline Engineering, 
2 CRISPR J. 134 (2019); HUMAN GERMLINE GENOME MODIFICATION AND THE RIGHT TO SCIENCE: 
A COMPARATIVE STUDY OF NATIONAL LAWS AND POLICIES (Andrea Boggio, Cesare P.R. Ro-
mano, & Jessica Almqvist eds., 2019). 
 5. Stephan Guttinger, Trust in Science: CRISPR-Cas9 and the Ban on Human Germline Ed-
iting, 24 SCI. AND ENG’G ETHICS 1077, 1083 (2018); Eric Lander et al., Adopt a Moratorium on 
Heritable Genome Editing, 567 NATURE 165 (2019); Carrie D. Wolinetz & Francis S. Collins, NIH 
Pro Germline Editing Moratorium, 567 NATURE 175 (2019). See also Edward Lanphier et al., 
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genome editing techniques have seen a faster development than the asso-
ciated ethical and regulatory evaluation of said techniques, the practical 
implementation of this technology raises questions about its ethical, legal, 
and social impact. In this respect, the medico-ethical issues surrounding 
this technology concern the justifiability of using or foregoing this tech-
nique in medicine, and the legal issues concern whether the current reg-
ulations of genetic engineering in medicine adequately reflect the use of 
this technology in view of its benefits and risks to individuals and society. 
It must also be clarified to what extent legal loopholes may make it pos-
sible to circumvent existing legal provisions aimed at ensuring the quality 
and safety of therapies. 
II.  THE SIGNIFICANCE OF SCIENTIFIC-TECHNICAL DETAILS FOR LEGAL 
ANALYSIS 
The technical character and the technical details of genome editing 
are usually overrated in the medico-ethical and legal assessment of ther-
apeutic genome editing. When addressing the ethical and legal issues re-
lated to the medical research and application of genome editing, the de-
tailed molecular genetic mechanisms are often disregarded. For the legal 
consideration, all that matters are the editing methods and their conse-
quences, without having to give a detailed description of which molecules 
of the editing tools will interact with which molecules of the target DNA. 
Even in the case of other genetic therapy methods, the mode of action at 
the level of individual atomic bonds and molecular bonds in the DNA is 
not examined in relation to genetic engineering legislation or pharmaceu-
tical legislation. Instead, the possibility of changing the information con-
tent of the DNA that is, or is supposed to be, affected by the respective 
method is examined; or reference is made to the effect on the DNA 
brought about by the specific method, usually in the form of a change in 
the linear sequence of the bases of the DNA. Thus, nothing else can apply 
for the medico-ethical and legal assessment and handling of genome ed-
iting. Rather, genome editing methods must be assessed in the same way 
as other genetic therapy methods to allow for a comparable legal assess-
ment. In addition, there are no reasons why the therapeutic effects of ge-
nome editing should be treated differently than other already established 
genetic engineering methods in terms of medical ethics or law. 
 
Don’t Edit The Human Germ Line, 519 NATURE 410 (2015); Michael McCarthy, Scientists Call 
For Moratorium on Clinical Use of Human Germline Editing, 351 BMJ, Dec. 7, 2015, at 1, File 
No. H6603. 
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That means in summary: in the context of the ethical, legal consid-
erations of the medical application of genome editing, molecular genetic 
instructions or descriptions of the mode of action are not necessary. For 
example, in the ethical, legal analysis of the well-known painkiller ace-
tylsalicylic acid, nobody would describe the molecular mode of action in 
detail simply to describe the ethics of this painkiller. The medico-ethical 
and legal analysis is instead based on the benefit-risk ratio of the use of 
this substance and not on the molecular mode of action (e.g., benefit: pain 
relief, risk: nausea, vomiting, diarrhea, and micro-bleeding in the diges-
tive tract). Therefore, as with all other therapeutic agents, the ethical and 
legal evaluation of the methods of genome editing is per se based on (sta-
tistically proven) benefit-risk studies, but not on the molecular genetic 
mode of action. 
III.  THE MULTILEVEL MATRIX OF THE STATUTORY PROVISIONS OF 
GENOME EDITING 
Six different classes emerge for answering the medico-ethical and 
legal framework of genome editing in medicine (see Table 1). This is 
achieved by distinguishing between a) using somatic cells or germline 
cells, b) doing basic research (e.g., non-therapeutic research using cells 
and animals) or preclinical research (e.g., therapy orientated research us-
ing cells and animals), and c) performing clinical research/studies (e.g., 
therapy orientated research on humans) or therapy application after mar-
ket authorization (e.g., routine use). The classes are the following: (1) 
non-clinical research using somatic human cells 6  (2) non-clinical re-
search using human germline cells, germ cells and embryos, (3) clinical 
research on somatic gene therapy, (4) clinical research on germline ther-
apy, (5) routine therapeutic application of somatic gene therapy, and (6) 








 6. Non-clinical as grouping of basic research and preclinical research. This grouping is use-
ful because the legal frameworks are similar. The main difference between the two is that preclin-
ical research also has to comply with the legally standardized requirements of the Good Laboratory 
Practice (GLP), which do not apply to basic research. 
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Table 1: matrix of the statutory regulation of medical genome editing in 
Germany 
non-clinical research1 clinical research therapy application 



















   








germline relevant germline relevant germline relevant 
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Table Footnotes: 
1    grouping of basic research and preclinical research 
2    EU: European Union 
3    EC: European Community 
 
The key legal provisions that cover these six areas can be found in Ger-
man law and EU law. Within German law, the Genetic Engineering Act 
(GEA),7 the Embryo Protection Act (EPA)8 and the Medicinal Products 
 
 7. Gentechnikgesetz [GenTG] [Genetic Engineering Act], Dec. 16, 1993, BGBl I at 2066, 
last amended by Verordnung [V], June 19, 2020, BGBl I at 1328, art. 95 (Ger.), http://www.ge-
setze-im-internet.de/gentg/BJNR110800990.html. 
 8. Embryonenschutzgesetz [ESchG] [Embryo Protection Act], Dec. 19, 1990, BGBl I at 
2746, last amended by Gesetz [G], Nov. 21, 2011, BGBl I at 2228, art. 1 (Ger.), http://www.gesetze-
im-internet.de/eschg/BJNR027460990.html. 
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Act (MPA)9 are of primary importance. When it comes to EU legislation, 
the pharmaceutical directive (Directive 2001/83/EC), 10  the advanced 
therapy medicinal products (ATMP) regulation (Regulation (EC) No. 
1394/2007)11 and the regulation on the marketing of medicinal products 
(Regulation (EC) No. 726/2004)12 must be considered. It is worth noting 
that Directive 2001/20/EC still applies in the EU for the legal manage-
ment of clinical studies.13 However, this directive will most likely be re-
placed in 2021 or 2022 by the already published Regulation (EU) No. 
536/2014.14 It is also worth noting that EU regulations are directly appli-
cable to all member states of the EU, which includes Germany. In con-
trast, EU directives are addressed first and foremost by the legislators of 
the member states, who have to transpose the provisions of the directives 
into national provisions for the harmonization of national laws. In this 
case, although the respective national provisions dictate the law, these 
will also contain provisions of EU law. The provisions referred to here, 
and that can be seen in Table 1, are only the essential provisions govern-
ing prohibitions and approval requirements for genome editing in human 
medicine. Table 1 does not offer a detailed description of the general leg-
islation that regulates informed consent, regardless of the medical proce-
dures used or data protection issues and ownership of donated cells. 
A.  Non-Clinical Research on Somatic Cells ①  
In Germany, the use of genome editing methods on somatic cells is 
neither a priority nor explicitly prohibited. Therefore, it is legally permis-
sible to use genome editing methods, on the condition that general legal 
provisions such as provisions concerning workplace and laboratory 
safety are observed. As with the other classes, genetic engineering 
 
 9. Arzneimittelgesetz [AMG] [Medicinal Products Act], Dec. 12, 2005, BGBl I at 1869, last 
amended by Gesetz [G], Dec. 9, 2020, BGBl I at 2870 (Ger.), http://www.gesetze-im-inter-
net.de/amg_1976/BJNR024480976.html. 
 10. Council Directive 2001/83, of the European Parliament and of the Council of 6 November 
2001 on the Community Code relating to Medicinal Products for Human Use. 
 11. Regulation (EC) 1394/2007, of the European Parliament and of the Council of 13 Novem-
ber 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Reg-
ulation (EC) 726/2004. 
 12. Council Regulation (EC) 726/2004, of the European Parliament and of the Council of 31 
March 2004 laying down Community Procedures for the Authorisation and Supervision of Medic-
inal Products for Human and Veterinary Use and Establishing a European Medicines Agency. 
 13. Council Directive 2001/20/EC, of the European Parliament and of the Council of 4 April 
2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member 
States relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on 
Medicinal Products for Human Use. 
 14. Regulation (EU) 536/2014, of the European Parliament of 16 April 2014 on Clinical Trials 
on Medicinal Products for Human Use and Repealing Directive 2001/20/EC. 
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laboratory activities must comply with the GEA provisions on the opera-
tion of genetic engineering laboratories.15 Legal questions in non-clinical 
research on the genetic modification of somatic cells using genome edit-
ing methods do not differ from legal questions in non-clinical research on 
the genetic modification of human cells using methods other than genome 
editing. In summary, the non-clinical use of human cells in combination 
with genome editing primarily involves questions of informed consent 
regarding cell donation and the use of the cells, data protection issues 
relating to genetic information gained from the donated cells, and ques-
tions of civil property rights regarding the donated cells. Reference may 
be made to the previous discussion on basic research and preclinical re-
search with somatic human cells.16 The current provisions in this area ap-
pear to cover genome editing adequately. Since the use of somatic human 
cells in genome editing research raises no new questions, this class can 
be regarded as medico-ethically and legally unproblematic. 
B.  Non-Clinical Research on Germline Cells, Germ Cells and Embryos 
②   
Targeted germline alterations on germline cells and germ cells are 
explicitly prohibited by the EPA in Germany;17 this ban applies to all 
methods and all objectives. Both genetic alterations, which are directed 
towards the therapy of hereditary diseases and interventions for enhance-
ment (improvement of human characteristics without reference to a dis-
ease), are covered and thus prohibited. The prohibition in the 1990 EPA 
already existed before genome editing came about.18 However, according 
to EPA Section 5.4 No. 1 and 2, using germline cells and germ cells for 
the scientific purpose of intentionally altering their genetic characteristics 
is permissible under certain conditions. This research is permissible if the 
researchers ensure that the genetically modified germ cells are not used 
for fertilization, that the altered germline cells are not transferred to an 
embryo, fetus, or human, or that no germ cells arise from them. 
 
 15. Genetic Engineering Act §§ 7-12. 
 16. Hannah B. Baker, John P. McQuilling & Nancy M. P. King, Ethical Considerations in 
Tissue Engineering Research: Case Studies in Translation, 99 METHODS 135, 137 (2016); ERWIN 
DEUTSCH & ANDREAS SPICKHOFF, MEDIZINRECHT, ARZTRECHT, ARZNEIMITTELRECHT, 
MEDIZINPRODUKTERECHT UND TRANSFUSIONSRECHT 805 (7th ed. 2014); Rob B.M. de Vries et 
al., Ethical Aspects of Tissue Engineering: A Review, 14 TISSUE ENG’G: PART B. 367, 370 (2008). 
See Rina Hakiman & David Korn, Ownership and Use of Tissue Specimens for Research, 292 
JAMA 2500 (2004). 
 17. Embryo Protection Act § 5(1). 
 18. Id. 
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Even so, advancing technologies have made it possible to circum-
vent these prohibitions.19 For such germline alterations, genome editing 
methods as well as other methods for DNA modification can be used. 
These methods must then be combined with other biotechnological and 
genetic engineering techniques to first produce oocytes and sperm cells 
that are not covered by the provisions of the EPA. The oocytes and sperm 
cells are not naturally derived from germline cells. Instead, they are de-
rived extracorporeally by methods of stem cell biology either from biop-
sied adult stem cells or from initially biopsied somatic cells, which are 
then transformed into induced pluripotent stem cells (iPS cells).20 The 
production of oocytes and sperm from stem cells is not covered by the 
EPA, neither for research purposes nor for therapeutic purposes, and 
therefore is not prohibited. The non-applicability of the EPA to artifi-
cially derived oocytes and sperm cells is justified by the fact that the 
EPA’s definition of germ cells (in EPA Section 8.3) is linked to a medical 
formation process explicitly described in the EPA: “For the purposes of 
this Act, germ line cells are all cells that lead in a cell line from the ferti-
lised egg to the egg and sperm cells of the human being resulting from 
this fertilised egg. . .”. In accordance with EPA Section 8.3, germ cells 
must originate from germline cells. Therefore, according to the EPA, 
germ line cells or germ cells can only be cells that originate from a (con-
tinuous) cell line, in other words, from the fertilized egg to the oocytes 
and the sperm cells of the human being that have also arisen from the 
fertilized egg. In addition, the oocyte may be a germline cell within the 
meaning of the EPA from the moment of sperm cell insertion or penetra-
tion until fertilization is completed with nuclear fusion.. Thus, the EPA 
has linked its legal definition of germline cells and germ cells to a specific 
development process and not to a functional description independent of 
the development process. In any case, this process, which is required by 
law, does not exist in both germline cells and germ cells produced from 
stem cells, other than the primordial germ cells in the germline. The law 
 
 19. See Timo Faltus & Ronny Schulz, Die arzneimittelrechtliche Handhabung zellbasierter 
Therapien in Point-of-Care-Behandlungsmodellen, 37 PHARMR 228 (2015); see also Timo Faltus, 
Rechtsrahmen der Eigenfettnutzung bei Point-of-Care-Behandlungen in der plastischen und ästhe-
tischen Chirurgie - Straf- und berufsrechtliche Risiken aufgrund des Arzneimittelrechts, 48 
HANDCHIRURGIE MIKROCHIRURGI PLASTICHE CHIRURGIE 219 (2016) [hereinafter Rechtsrahmen 
der Eigenfettnutzung bei]. 
 20. Saskia Hendriks et al., Artificial Gametes: A Systematic Review of Biological Progress 
Towards Clinical Application, 21 HUM. REPROD. UPDATE 285 (2015); Javad Amini Mahabadi et 
al., Derivation of Male Germ Cells from Induced Pluripotent Stem Cells by Inducers: A Review, 20 
CYTOTHERAPY 279 (2018); Immaculda Moreno et al., Artificial Gametes from Stem Cells, 42 
CLINICAL AND EXPERIMENTAL REPROD. MED. 33 (2015). 
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would need to be amended to change the description of germ cells to a 
function-based model in order to account for artificially produced 
germline cells and germ cells in the scope of the EPA, as well as make 
corresponding prohibitions—such as sections 5.1 and 5.2 of the EPA—
legally binding for artificially produced germline cells.21 However, prior 
to any amendment of section 8.3 of the EPA, the current legal require-
ments still apply (i.e., a) the statutory prohibitions of the EPA regarding 
germline changes (in section 5), which refer only to naturally occurring 
germline cells and germ cells because of the link to the EPA’s definition 
of germ cells in section 8.3 of EPA, and b) the current legal requirements 
must not be applied to artificially produced germline cells or germ cells.). 
This non-applicability of the EPA stems also from the constitutional ban 
on using analogies to the detriment of the acting person (Art. 103.2 of the 
German Basic Law which serves as the German Constitution). According 
to this constitutional provision, only such action may be punished which 
was prohibited by law before the action (general rule: nulla poena sine 
lege stricta). The application of the prohibition on the therapeutic use of 
genetically modified germ cells with respect to artificially produced germ 
cells would only be possible if the relevant prohibition of the EPA could 
be applied by analogy. This is due to the fact that in this case only the 
meaning (i.e., artificial intervention into the germ line) of the described 
criminal provision would be decisive for its application. However, this 
application would go beyond the literal sense of the provision (i.e., natu-
rally arising gametes). Although, as shown, such an analogous applica-
tion is prohibited. 
Finally, for the inclusion of artificially produced germ cells or 
germline cells in the scope of the EPA, the argument does not apply that 
artificially produced germline cells and germ cells must be covered by 
the EPA or else the resulting embryo or later born human would not have 
originated from germ cells. This argument confuses the legal/policy field 
with the scientific/empirical field. There is neither a lawful nor a non-
lawful reason why these two fields must be congruent in content. There 
are no reasons why the actual (and legal) existence of a born human being 
must necessarily be bound to the legal existence of germ cells. Due to a 
lack of legal prohibitions, artificially produced germline cells and germ 
cells can be used to a legally permissible extent even beyond what is per-
missible with naturally occurring germline cells or germ cells. On the one 
hand, artificially produced germline cells and germ cells could be legally 
 
 21. TIMO FALTUS, STAMMZELLENREPROGRAMMIERUNG - DER RECHTLICHE STATUS UND 
DIE RECHTLICHE HANDHABUNG SOWIE DIE RECHTSSYSTEMATISCHE BEDEUTUNG 
REPROGRAMMIERTER STAMMZELLEN 392, 459 (2016). 
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genetically modified. On the other hand, in contrast to naturally occurring 
germline cells or germ cells after their genetic modification, these edited 
cells could also be transferred to an embryo or to humans. Genetically 
modified germ cells could even be used for fertilization purposes. If this 
contradiction is to be eliminated, then this can only be done by an amend-
ment to the law as described above. 
Germline genetic changes of embryos for research on genome edit-
ing are also prohibited by the EPA.22 With regard to the use of genome 
editing procedures in extracorporeal embryos, there are several legal 
loopholes as a result of the time discrepancy between technical progress 
and the resilience of required legislative amendments. In addition, these 
loopholes also arise from the above-mentioned prohibition of the use of 
analogous criminal prohibitions, which makes possible the use of genome 
editing in extracorporeal embryos which were not recognized by the leg-
islators when the EPA was enacted. 
For embryos that are sexually derived from naturally occurring germ 
cells (i.e., germ cells within the meaning of the EPA as described above), 
the prohibition of germline manipulation is safeguarded in two respects. 
Single-cell embryos (i.e., fertilized egg cell) and totipotent cells in a mul-
ticellular embryo are also considered germline cells (EPA Section 8.3), 
meaning that artificial changes of their genetics would constitute a for-
bidden germline change according to section 5.1 of the EPA. It is further 
prohibited under section 2.1 of the EPA to use an extracorporeally created 
embryo for purposes other than the preservation of the embryo. The ex-
perimental use of editing methods on embryos does not serve to preserve 
these embryos, which means that corresponding actions are prohibited 
and can be punished with imprisonment of up to three years or with a fine 
under section 2.1 of the EPA. The relationship between EPA Sections 5.1 
2.1 leads to unsolved legal problems in the case of targeted alterations of 
the germline of embryos for the treatment of the genetic basis of a hered-
itary disease. Such a genetic alteration could possibly be compatible with 
Section 2.1 of the EPA,23 but such an alteration would always be prohib-
ited by section 5.1 of the EPA. Therefore, if the causal therapy of hered-
itary diseases in the embryo is to be legally permissible in the future, these 
two provisions would have to be aligned with each other by amending the 
EPA. 
However, the prohibitions of the misuse of embryos described 
above only apply if the embryo entities in question are considered 
 
 22. Embryo Protection Act § 5. 
 23. “Anyone who uses an extracorporeally created embryo for a purpose that does not serve 
its preservation will be punished.” 
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embryos under the EPA. In that regard, similar to the use of artificially 
produced germline cells, there are legal problems relating to bypassing 
legal prohibitions. The application of genome editing to embryos (in a 
medical, empirical sense) is permitted in Germany if the entities con-
cerned are not considered embryos under the EPA. Section 8.1 of the EPA 
defines what constitutes an embryo. Accordingly, for the purpose of this 
Act, the meaning of an embryo shall encompass the human egg cell, fer-
tilized and capable of developing, from the time of fusion of the nuclei, 
as well as any totipotent cell removed from an embryo that is capable of 
dividing and developing into an individual under appropriate conditions. 
This legal definition thus refers to the sexual origin of an embryo, and 
states that, the entities in question also have to be able to develop. Asex-
ually derived entities, such as embryos from somatic cell nucleus transfer 
(Dolly method) or “synthetic human entities with embryo-like features” 
(SHEEFs),24 are not considered embryos under the EPA by the majority 
of legal scholars.25 In contrast to sexually created embryos, genome edit-
ing studies could be carried out on such asexually derived embryos if they 
were produced with human cells. If this contradiction is to be eliminated, 
it can only be done by an amendment to the EPA. 
It is disputed in Germany whether sexually and asexually produced 
embryos may be used for research on germline alterations if they are em-
bryos that are inhibited in their development in such a way that no born 
human can arise from them. If such embryos are entities that were derived 
asexually (i.e., without fusion of oocyte and sperm cell), then, as de-
scribed above, one must assume that such entities are not covered by the 
prohibitions of the EPA. It becomes more complex when tripronuclear 
embryos (3PN zygotes) are involved, which have already been genet-
ically modified outside Germany with genome editing methods.26 In prin-
ciple, these 3PN zygotes are sexually derived embryos, so they are cov-
ered by the legal embryo definition within the EPA. Consequently, 
prohibitions regarding the misuse of embryos and the prohibition of 
germline alteration must be taken into account. Only when a 3PN zygote 
(as well as all other sexually created embryos) stops its further develop-
ment on its own (i.e., showing no more cell divisions), will the respective 
 
 24. See John Aach et al., Addressing the Ethical Issues Raised by Synthetic Human Entities 
with Embryo-like Features, ELIFE, Mar. 21, 2017, at 1, File No. e20674. 
 25. For a list of further references with different views, see FALTUS, supra note 21, at 374-83, 
387-93. 
 26. For genome editing advances in China using 3PN zygotes, see Puping Liang et al., 
CRISPR/Cas9-Mediated Gene Editing in Human Tripronuclear Zygotes, 6 PROTEIN CELL 363 
(2015) and Changyang Zhou et al., Highly Efficient Base Editing in Human Tripronuclear Zygotes, 
8 PROTEIN CELL 772 (2017). 
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3PN zygote no longer be considered an embryo under the EPA. A pro-
spective assessment of the developmental stop, even if it is sure to occur, 
does not legally justify the use of that embryo for research purposes. Pro-
vided that new research possibilities are to be created in a legally secure 
manner, the existing legal definition of embryos in section 8.1 of the EPA 
with regard to the embryo’s development capacity would have to be 
amended from the abstract, open-ended wording to a wording with a spe-
cific development stage. This specific wording would have to name a cer-
tain state of development (e.g., formation of the neural tube). If, on the 
basis of empirical observations, it was established that certain embryos 
could not reach a specific, legally definable stage of development in spe-
cific situations, then these embryos could possibly be used for research 
purposes. From an ethical point of view, this would also entail that the 
developmental phases prior to this specific state are not worthy of moral 
protection (like born human beings are). 
Another discussion concerns the legal status of embryos created in 
vitro from artificially created germ cells. If two artificially produced germ 
cells (i.e., egg cell and sperm cell) are used, then the process of embryo 
generation is indeed sexual, which in principle means that an embryo as 
defined by the EPA may be present. The problem with this is that, as 
mentioned above, such artificially generated germ cells are not germ cells 
in the sense of the law. The unresolved question arises as to whether an 
embryo within the meaning of the EPA can develop from germ cells, 
which are not germ cells under this Act. These questions become even 
more complex if one of the germ cells is naturally developed, but the 
other germ cell is artificially produced. So far, these are merely academic 
considerations, as the practical implementation does not (yet) seem to be 
technically mature and because physicians and scientists concerned are 
certainly also deterred by the legal situation from attempting it. These 
academic questions about the legal status of embryos, which are based on 
the use of artificially produced germ cells, would dissolve only at the mo-
ment when the embryos in question would have been transferred to a 
woman and have implanted in the uterus. This is because the EPA is no 
longer applicable once an embryo is implanted in the uterus. Instead, the 
German Criminal Code’s provisions on abortion is relevant (Section 218-
2019b). The Criminal Code does not refer to the creation of an embryo, 
and the Criminal Code does not even use the term “embryo,” only refer-
ring to “nidation” and “pregnancy.”27 Put simply, a pregnancy under the 
 
 27. See generally Strafgesetzbuch [StGB] [German Criminal Code], last amended by Gesetz 
[G], Mar. 30, 2021, BGBl I. 844, art. 1, https://www.gesetze-im-internet.de/stgb/ (Ger.) (using “ni-
dation” and “pregnancy” multiple times throughout the Code). 
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Criminal Code occurs as soon as an embryo is implanted in the uterus.28 
Based on this general formulation, all embryos, regardless of their tech-
nical origin, would be covered by the Criminal Code. 
C.  Clinical Research on Somatic Gene Therapy ③ 
For clinical research on somatic gene therapy, both with and without 
genome editing, the same criteria for clinical research on other therapies 
apply, requiring statistically proven efficacy, safety, and quality. For sub-
sequent market approval, a benefit/risk assessment appropriate to the par-
ticular clinical picture and the patient group should be carried out in clin-
ical trials. Clinical trials are standardized by law in the EU and in 
Germany. The respective provisions can currently still be found in the EU 
Directive 2001/20/EC. In Germany, the provisions from this EU Di-
rective are contained in the German Medicinal Products Act as well as in 
the German Good Clinical Practice Executive Order. It is anticipated that 
from 2020 the existing provisions of the EU Directive will be replaced 
by the already published EU Regulation No. 536/2014. 
In relation to medical ethics and the legal requirements for carrying 
out a clinical trial, the following general provisions must be observed as 
in any other gene therapy clinical trial: in accordance with the provisions 
of pharmaceutical legislation, a clinical trial may only be conducted if 
approval from the responsible ethics committee and approval from the 
competent medicinal products authority have been obtained. The ethics 
committee must weigh the benefit of the study against a potential risk to 
the participants. It also verifies that the medical facilities where the study 
will take place are appropriate and that their medical staff has the neces-
sary qualifications and experience for the study. The ethics committee 
also checks whether the written explanations on informed consent are 
comprehensible for the participants of the study and whether the partici-
pants’ written declarations of consent are complete. Only when these con-
ditions are met will the ethics committee give its consent to carry out the 
study. In addition, it is required that the competent medicinal products 
authority has positively evaluated the clinical trial from a medical point 
of view. 
D.  Clinical Research with Targeted Germline Alteration ④ 
In clinical research on targeted germline gene alteration, four cate-
gories must be distinguished: a) clinical studies with born humans, b) 
clinical studies using edited germ cells and generation of respective 
 
 28. See German Criminal Code (Ger.), § 218, para. 1. 
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edited embryos, c) editing alterations on an embryo in utero, and d) ge-
nome-editing alterations on an embryo in vitro with subsequent transfer 
of the edited embryo. In the case of born humans, clinical studies that 
lead to a change in the genetic germline identity of the participant may 
not be performed in accordance with the currently applicable EU Di-
rective 2001/20/EC 29  or in accordance with EU Regulation No. 
536/2014.30 Whether the targeted germline editing is additionally prohib-
ited by the German EPA is disputed, as the provisions of the EPA and its 
prohibitions on targeted germline manipulation were enacted to regulate 
the manipulation of germline cells and germ cells in vitro. Whether these 
provisions also apply to born humans seems questionable. At least with 
regard to born humans, in the case of germline altering interventions, it 
is always necessary to consider the general bans on bodily harm of the 
German Criminal Code. (see Part F). 
There are no independent legal provisions that regulate or explicitly 
prohibit germline-altering interventions on an embryo in utero. Whether 
the provisions of the EPA are applicable is also disputed since this law 
was not adopted for the regulation of handling embryos in vivo/in utero. 
The provisions on abortion from the Criminal Code should be considered, 
however. For example, if the germline alteration of the embryo in utero 
would cause the abortion and this would not be in accordance with the 
consent of the mother, it could be a prohibited and punishable abortion.31 
Regarding embryos in utero, it is also questionable whether the prohibi-
tions under the mentioned EU law should be observed in the conduct of 
clinical studies leading to a change in the participant’s genetic germline 
identity. It is unclear whether these rules are also applicable to embryos 
(whether in utero or in vitro). Applicability requires that embryos would 
be regarded as study participants; in other words, embryos would have to 
be treated, in legal terms, as born human beings as the wording of these 
EU acts refers to study participants.32 
In contrast, clinical research on germline-relevant alterations on em-
bryos in vitro is explicitly prohibited by the EPA, and possibly by regu-
lations governing clinical trials. Although genome editing is not explic-
itly mentioned in the provisions of the EPA, the corresponding 
procedures are nevertheless covered since Section 5.1 of the EPA 
 
 29. Directive 2001/20/EC, supra note 13, art. 9.6. 
 30. Regulation (EU) 536/2014, supra note 14, art. 90. 
 31. German Criminal Code (Ger.), § 218, para. 2, sentence 1. 
 32. Timo Faltus, No Patent-No Therapy: A Matter of Moral and Legal Consistency Within the 
European Union Regarding the use of Human Embryonic Stem Cells, 23 STEM CELLS AND DEV. 
56, 58 (2014); FALTUS, supra note 21, at 730-39. 
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generally prohibits the artificial alteration of the genetic information of 
human germline cells and germ cells. The ban is ethically justified since 
its adoption, inter alia, by the argument that germline therapy methods 
cannot be developed without previous experiments on humans. However, 
such studies would not be justifiable because of the potentially irreversi-
ble consequences in the experimental phase (failures with non-excludable 
genetic damages to the participant).33 In addition, as for non-clinical re-
search, it should be noted that the use of human embryos for research 
purposes is prohibited in Germany without exception under Section 2.1 
of the EPA.One must keep in mind that there are the above mentioned 
and yet unanswered questions as to whether the EU’s prohibitions of clin-
ical trials involving gene therapies that lead to an altered genetic germline 
identity of the trial participant can also be applied to embryos. The state-
ments made under Part B apply with regard to the legal issues, in partic-
ular with regard to the technical possibilities for circumventing the legal 
prohibitions on the use of edited germ cells in clinical trials. 
E.  Somatic Therapy Application of Genome Editing ⑤ 
Therapeutics based on genome editing are, in legal terms, usually 
gene therapeutics. This assessment is based on article 2.1of the ATMP 
Regulation in conjunction with part one of annex one to Directive 
2001/83/EC. Accordingly, a gene therapeutic is to be understood as a bi-
ological medicinal product with the following characteristics: 
(a) it contains an active substance which contains or consists of a 
recombinant nucleic acid used in or administered to human beings with a 
view to regulating, repairing, replacing, adding or deleting a genetic se-
quence; (b) its therapeutic, prophylactic or diagnostic effect relates di-
rectly to the recombinant nucleic acid sequence it contains, or to the prod-
uct of genetic expression of this sequence.34 
Yet the multitude of therapeutic uses of genome editing procedures 
do not allow for a general classification of these methods as gene thera-
peutics. For this purpose, rather, a case-by-case assessment with regard 
to the respective therapeutic is necessary. If, in some cases, the therapeu-
tic in question is not a gene therapeutic, it must be examined whether this 
 
 33. Hubert Schorle & Frank Tüttelmann, “Gene-Editing”-Verfahren - Stellungnahme der 
DVR-Mitglieder AAD, ADI, AGRBM, DGA, DGGEF, D.I.R, SRBM und SEF unter Federführung 
der DGRM, 13 JOURNAL FÜR REPRODUKTIONSMEDIZIN UND ENDOKRINOLOGIE 18 (2016); Geset-
zentwurf der Bundesregierung [Bill of the Federal Government], Bundestagsdrucksache [Printed 
Matters of the German Federal Parliament] 11/5460, at 11, http://www.dip21.bundes-
tag.de/dip21/btd/11/054/1105460.pdf (Ger.). 
 34. Directive 2001/83, supra note 10, art. 2.1. 
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therapeutic, which is using genome editing, is a somatic cell therapy in 
accordance with article 2.1.a of the ATMP Regulation and part four of 
annex one of Directive 2001/83/EC, or whether the therapeutic is a bio-
technologically processed tissue product in accordance with articles 2.1.a 
and 2.1.b of the ATMP Regulation. Legally speaking, not every genet-
ically engineered cell or derived therapeutic will automatically be con-
sidered gene therapy, even if there are detectable genetic changes in the 
therapeutic cells. Instead, they might be considered genetically engi-
neered cells within one of the two latter classes of medicinal products.35 
In the EU, ATMP manufacturing requires that a manufacturing li-
cense be issued by local pharmaceutics authorities.36 Manufacturing must 
then take place under Good Manufacturing Practice (GMP) conditions 
(article 5 of the ATMP Regulation). ATMP may only be placed on the 
market in the EU after official market approval per articles 27 and 28 of 
the ATMP Regulation, and article 3 of Regulation (EC) No. 726/2004. 
Thus, the regular therapy application of such therapeutics is possible only 
after market approval. Among other things, the granting of approval re-
quires that the therapeutic in question has been successfully tested in a 
preclinical and clinical environment. Regarding the regulatory manage-
ment of the therapeutic application of genome editing, however, the ques-
tions of the legal, and thus ethical, requirements of the corresponding 
clinical studies or market approval are often addressed too quickly. Such 
considerations overlook current technological developments in the field 
of therapeutic application of cell-based therapeutics, and more specifi-
cally, in the application of genome editing. Legal issues of clinical trials 
and the market approval of medicinal products only arise when the me-
dicinal product in question is placed on the market in legal terms. Both 
EU law and the German Medicinal Products Act explicitly refer to the act 
of placing them on the market.37 It follows that a medicinal product that 
is not legally placed on the market is not subject to market authorization 
and can therefore be used without it. For some time now, technological 
advances in the fields of ATMP production and use have made it possible 
to offer ATMP that are not placed on the market in legal terms. This 
would be the case in particular when the therapeutic is manufactured by 
a physician, then applied to his patient by the physician or under the su-
pervision of the physician that manufactured the pharmaceutical. From a 
 
 35. Brigitte Anliker et al., Genetisch modifizierte Zellen zur Therapie verschiedener 
Erkrankungen 58 BUNDGESUNDHEITSBL 1274 (2015). 
 36. Regulation (EC) 1394/2007, supra note 11, art. 5. 
 37. Cf. Directive 2001/83/EC, supra note 10, art. 2.1; Regulation (EC) 726/2004, supra note 
12, art. 3.1; Regulation (EC) No. 726/2004; Medicinal Products Act § 1. 
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legal point of view, for example in Germany, this procedure is not con-
sidered placement on the market, since placement on the market presup-
poses a transfer of power of disposition of the therapeutic. Yet if a phy-
sician personally manufactures a medicinal product and applies it to a 
patient, the patient cannot then dispose of the medicinal product to an-
other person. 
In recent years, technological advances have made it possible to 
quickly develop technical devices that allow the manufacturing and ap-
plication of gene therapeutics at the point-of-care. Such technical devices 
are already available to physicians, and corresponding medical literature 
is available regarding the usage of this technique. 38The manufacture and 
use of somatic gene therapeutics based on genome editing can also be 
carried out without placing them on the market. After all, the scientific 
discourse regularly emphasizes the technical simplifications offered by 
genome editing methods for the targeted generation of very specific ge-
netic modifications. As a result of this simplification, it is possible that a 
significant portion of somatic gene therapeutics may not legally require 
clinical trials or market approval. Nevertheless, they may still be used in 
therapy. The regulatory discussion on the medical and legal handling of 
the editing methods should therefore also include the growing sector of 
in-house medicinal product manufacturing and should begin to develop a 
regulatory approach to control and ensure quality, safety, and efficacy of 
therapeutics. However, from a medico-ethical point of view, this devel-
opment is questionable because physicians’ privileged regulatory ap-
proach to manufacturing of medicinal products may become the factual 
norm. Even so, the regular use of a medicinal product requires, among 
other things, a statistically verified development in preclinical and clini-
cal studies in order to guarantee a certain level of safety. 
Today, a general prohibition from the Medicinal Products Act is 
available to prevent such clinically unproven therapies. In accordance 
with section 5 of the MPA, placement on the market or the use of unsafe 
medicinal products on another human is prohibited. Medicinal products 
are considered unsafe if, according to the current level of scientific 
knowledge, there is a sufficient reason to suspect that when used in ac-
cordance with their intended purpose they have harmful effects that 
 
 38. See Jennifer E Adair et al., A Point-of-Care Platform for Hematopoietic Stem Cell Gene 
Therapy, 126 BLOOD 4416 (2015) [hereinafter Adair et al., A Point-of-Care Platform]. See also 
Jennifer E Adair et al., Semi-automated Closed System Manufacturing of Lentivirus Gene-modified 
Haematopoietic Stem Cells for Gene Therapy, 7 NATURE COMMC’NS, Oct. 2016, at 1 (2016) [here-
inafter Adair et al., Semi-automated Closed System Manufacturing]. See generally Opening the 
Door to Backroom Biologics, 37 NATURE BIOTECHNOLOGY 1097 (2019). 
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exceed the tolerable limit in light of current medical knowledge.39 The 
determination of whether the same logic applies to somatic genetic ther-
apies that are manufactured by physicians depends on a case-by-case 
evaluation. 
If one assumes, concerning somatic cells, that substances for en-
hancement by means of genetic engineering procedures such as genome 
editing are also medicinal products in the legal sense, then it is question-
able whether an “unknown substance” would be given the necessary au-
thorization to conduct clinical studies solely to investigate purposes of 
enhancement. It seems questionable whether there is justification for ex-
posing people to the unknown health risks of an undisclosed substance or 
an unknown treatment method in clinical studies simply to test whether a 
genetic, physiological, or neurological enhancement may be achieved. Ir-
respective of the question whether enhancement is a medicinal product in 
the legal sense, it is always questionable whether enhancement has an 
effect on the human body that is compatible with criminal law or whether 
it is (already) a punishable bodily harm (see Part F). More problematic in 
genetic enhancement are cases of genetic modification carried out on the 
patient’s own body, which have become possible through technical sim-
plifications in the field of genome editing.40 Cases of deliberate self-en-
dangerment are not yet able to be addressed by pharmaceutical or crimi-
nal law, and thus, are not regulated by any law, so long as there is no third 
person endangerment. 
F.  Therapeutic Germline Application ⑥ 
As with the questions on the clinical examination of targeted 
germline alteration, various constellations are also possible when it 
comes to therapeutic application. The legal handling of these constella-
tions is basically to be evaluated as described under Part D. As for the use 
of germline therapeutics in born humans, the prohibition relating to un-
safe medicinal products (section 5 of the MPA) should be considered as 
described in Part E, in addition to the aspects mentioned in Part D. 
Whether such an unsafe medicinal product, whether for the treatment of 
hereditary diseases or purposes of enhancement, is present in a targeted 
germline alteration in born humans has yet to be answered. Furthermore, 
born humans are protected against assault and battery by sections 223, 
224, and 226 of the Criminal Code These general provisions include 
 
 39. Medicinal Products Act § 5(2). 
 40. Eric Smalley, FDA Warns Public of Dangers of DIY Gene Therapy, 36 NATURE 
BIOTECHNOLOGY 119 (2018); Opening the Door to Backroom Biologics, supra note 38. 
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protection against targeted and unwanted germline change. However, it 
is questionable how targeted germline changes that a patient desires will 
be assessed according to the Criminal Code. Whether such a germline 
change would satisfy the criminal offense of bodily harm depends on 
whether the patient consented to such treatment, rendering the change not 
punishable under section 228 of the Criminal Code, or whether, despite 
consent, the treatment violates moral standards, rendering such change 
punishable. How such a germline change would violate moral standards 
must be clarified—as for the question of unsafe medicinal products per 
section 5 of the MPA—by the medical field and the ELSI disciplines. 
Concerning the therapeutic application of genome editing to germ 
cells and embryos, the comments made in Part B regarding the complex 
interplay between sections 5.1 and 2.1 of the EPA, and the comments on 
Clinical Research with Targeted Germline Alteration in Part D apply. 
Moreover, the following should be considered: Even if Germany permit-
ted germline therapy under the EPA in sections 2.1 and 5.1 (see Part B), 
the development of appropriate therapies is unlikely to be legally possible 
because the conduct of necessary clinical studies in the EU as described 
in Part D is excluded. Market approval is not possible without clinical 
studies. In Germany, this legal restriction could be bypassed by using 
germline therapeutics which are not placed on the market in legal terms, 
such as therapeutics manufactured and used by physicians in-house. For 
these germline therapeutics, no clinical studies or market approval is nec-
essary. In addition, there are legal loopholes in the current legislation for 
the therapeutic application of genome editing, which arise from using ar-
tificially produced germ cells from stem cells as described in Part B. 
Germ cells derived from stem cells do not exist under the EPA, and thus, 
they can be genetically edited and legally used for therapeutic purposes. 
As a result of such loopholes in the law, germline therapy prohibited by 
the legislature could be possible. It is therefore the legislature’s task to 
close this gap by applying the same rules to artificial germ cells as applied 
to naturally occurring germ cells. 
The international moratorium to stop the implementation of 
germline alterations by genome editing would apply only to cases not al-
ready prohibited by German law. However, in Germany, many options 
for germline therapies are already prohibited by law. Thus, neither a mor-
atorium nor further statutory prohibitions are necessary. Legislators could 
include cases that are not already covered by the current prohibitions due 
to technological advances that have occurred since the initial enactment 
of the relevant laws by amending the existing legislation and expressly 
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prohibiting the current uncovered cases. This approach would be more 
legally secure than a moratorium. 
IV.  OUTLOOK 
The application-oriented development of genome editing in medi-
cine is—similar to the previous discovery, research and clinical applica-
bility of iPS cells—important not only for the sciences, medicine and 
technology, but also for the ELSI disciplines. Just as iPS cells were a 
catalyst for discussing, among other things, the meaning of iPS cells for 
the further use of human embryonic stem cells, genome editing is the cat-
alyst for the ELSI disciplines discussing the meaning this technology will 
have for the further development of genetic medicine. Although genome 
editing and iPS technology are already merging,41 ELSI work in these ar-
eas is still needed. It remains to be seen if the ELSI questions in these 
areas will turn out to be nothing more than fictitious giants, which on 
closer inspection become smaller because the supposed ELSI problems 
are not so different from previous ELSI assessments of earlier technolo-
gies with social implications. Instead, ELSI questions in medical genome 
editing could be comparable to previous questions researchers dealt with. 
New ELSI solutions will be necessary only if it turns out that there are 
completely new questions. In any case, the respective ELSI studies and 
their recommendations are important for the further development of ther-
apy, so that therapies can be developed that are socially acceptable be-
yond their technical feasibility. 
V.  TRANSLATED GERMAN LEGAL ACTS 
A.  Extract from the Basic Law for the Federal Republic of Germany 
Article 103 
(1)  In the courts every person shall be entitled to a hearing in accordance 
with law. 
(2)  An act may be punished only if it was defined by a law as a criminal 
offence before the act was committed. 
(3)  No person may be punished for the same act more than once under 
the general criminal laws. 
 
 41. Morgan L. Maeder & Charles A. Gersbach, Genome-Editing Technologies for Gene and 
Cell Therapy, 24 MOLECULAR THERAPY 430, 439 (2016). See Matthew H. Porteus, Towards a New 
Era in Medicine: Therapeutic Genome Editing, 16 GENOME BIOLOGY 286 (2015). 
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B.  Extract from the German Criminal Code 
Section 218 - Abortion 
(1)  Whoever terminates a pregnancy incurs a penalty of imprisonment 
for a term not exceeding three years or a fine. Acts whose effects occur 
before nidation is completed are not deemed to be a termination of preg-
nancy within the meaning of this statute. 
(2)  In especially serious cases, the penalty is imprisonment for a term of 
between six months and five years. An especially serious case typically 
occurs where the offender 
1.  acts against the will of the pregnant woman or 
2. recklessly places the pregnant woman in danger of death or at risk 
of serious damage to health. 
(3)  If the act is committed by the pregnant woman, the penalty is impris-
onment for a term not exceeding one year or a fine. 
(4)  The attempt is punishable. The pregnant woman is not liable for at-
tempt. 
Section 223 - Bodily harm 
(1)  Whoever physically assaults or damages the health of another person 
incurs a penalty of imprisonment for a term not exceeding five years or a 
fine. 
(2)  The attempt is punishable. 
Section 224 - Dangerous bodily harm 
(1)  Whoever causes bodily harm  
1.  by administering poison or other substances which are harmful 
to health, 
2.  using a weapon or other dangerous implement, 
3.  by means of a treacherous assault, 
4.  acting jointly with another party to the offence or 
5.  using methods which pose a danger to life incurs a penalty of 
imprisonment for a term of between six months and 10 years, in 
less serious cases imprisonment for a term of between three months 
and five years. 
(2)  The attempt is punishable. 
Section 228 - Consent 
Whoever inflicts bodily harm with the victim’s consent is only deemed 
to act unlawfully if, despite that consent, the act offends common de-
cency. 
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C.  Extract from the German Embryo Protection Act 
Section 2 - Improper use of human embryos 
(1)  Anyone who disposes of, or hands over or acquires or uses for a pur-
pose not serving its preservation, a human embryo produced outside the 
body, or removed from a woman before the completion of implantation 
in the uterus, shall be punished with imprisonment of up to three years or 
a fine. 
(2)  Anyone who causes a human embryo to develop further outside the 
body for any purpose other than to bring about a pregnancy shall be pun-
ished likewise. 
(3) Any attempt shall be punishable. 
Section 5 - Artificial alteration of human germ line cells 
(1)  Anyone who artificially alters the genetic information of a human 
germ line cell shall be punished with imprisonment of up to five years or 
a fine. 
(2)  The same shall apply to anyone who uses a human germ cell with 
artificially altered genetic information for the purpose of fertilization  
(3)  Any attempt shall be punishable. 
(4)  Paragraph 1 shall not apply to 
1.  an artificial alteration of the genetic information of a germ cell 
located outside the body, if any use of it for fertilization has been 
rule out, 
2.  an artificial alteration of the genetic information of a different 
body germline cell that has been removed from a dead embryo, 
from a human being or from a deceased person, if it has been ruled 
out that 
a.  the cell will be transferred to an embryo, fetus or human be-
ing, or 
b.  a germ cell will originate from it, as well as 
3.  an inoculation, radiation, chemotherapeutic or other treatment 
by which an alteration of the genetic information of germ line cells 
is not intended. 
Section 8 - Definition 
(1)  For the purpose of this Act, an embryo shall already mean the human 
egg cell, fertilized and capable of developing, from the time of fusion of 
the nuclei, as well as any totipotent cell removed from an embryo that is 
capable of dividing and developing into an individual under appropriate 
conditions. 
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(2)  In the first twenty-four hours after the fusion of nuclei, the fertilized 
human egg cell is held to be capable of development except if it is estab-
lished before expiration of this time period that the egg cell will not be 
capable of developing beyond the one cell stage. 
(3)  Germ line cells, for the purpose of this Act, shall be any cells that 
lead directly from the fertilized egg cell to the egg and sperm cells of the 
resultant human being and also egg cells from insertion or penetration of 
the sperm cell until the completion of fertilization by fusion of the nuclei. 
